• Record sales orders of $63.4 million, up 22% on FY24
• Sleep & Neurology segment orders rose 39%, led by 102% growth in US Sleep Diagnostics
• SaaS orders increased 49%, with US Somfit sales orders up 675%

Compumedics Limited (ASX:CMP) has provided a business update highlighting a breakout FY25 that marks a strategic turning point for the Company. Key highlights include record sales orders of $63.4 million, up 22% on FY24, with the Sleep & Neurology segment orders rising 39%, led by 102% growth in US Sleep Diagnostics. The Somfit + Nexus 360 SaaS orders increased 49%, with US Somfit sales orders rising 675% from $0.4 million to $3.1 million. The Company also reported record revenue of $51.0 million, up 4% on FY24, and a return to profitability with EBITDA of approximately $3 million. This was driven by product mix optimisation, scaling SaaS, and stable overheads. Compumedics is positioned to scale into a more focused, higher-margin business model underpinned by recurring revenues, new product launches, and MEG system deliveries. The Company reaffirmed its FY26 guidance of revenue of at least $70 million and EBITDA of approximately $9 million, with SaaS and connected platforms expected to contribute over 20% of group revenue.

FY26 revenue: at least $70 million FY26 EBITDA: approximately $9 million

SaaS and connected platforms (Somfit + Nexus 360 segment) are expected to contribute >20% of group revenue, delivering high margins and scalability. The disposable Somfit (Somfit D) launch in the US is expected to increase penetration of the 3-4 million unit per annum Home Sleep Test market, representing a $150 million to $300 million opportunity. Three MEG systems are on track for FY26 revenue, with paediatric market expansion increasing MEG opportunity to ~$120 million.